Amicus Therapeutics to Present at the Bank of America 2022 Healthcare Conference
May 04, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, May 04, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2022 Healthcare...
Amicus Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
April 26, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, April 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 9, 2022 at 8:30...
Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent Protection Through 2038
April 19, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, April 19, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference
March 16, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk and Forced Vital Capacity for ERT-Naïve and ERT-Experienced Patients Out to 3 Years Consistent Reduction in Biomarkers Continue...
Amicus Therapeutics Announces Presentation and Posters at the 2022 MDA Clinical & Scientific Conference
March 10, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will...
Amicus Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
March 01, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Cowen...
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
February 24, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
Galafold® Revenue Growth of 17% YoY to $306M in 2021 Galafold Global Sales Growing at Double-Digits (15-20%) with $350M-$365M in 2022 U.S. and EU Regulatory Filings Under Review and Launch...
Amicus Therapeutics to Announce Full-Year 2021 Financial Results on February 24, 2022
February 10, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 24, 2022...
Amicus Therapeutics Announces Presentations and Posters at the 18th Annual WORLDSymposium™ 2022
February 07, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance
January 10, 2022 07:00 ET
|
Amicus Therapeutics, Inc.
Full-Year 2021 Galafold® Revenue of ~$306M, Representing 17% YoY Growth Expect Double-Digit Growth (15-20%) of 2022 Galafold Revenue with $350M-$365M in Global Sales U.S. and EU Regulatory Reviews...